What We Have Learned about Autism Spectrum Disorder from Valproic Acid
Date
2013-12-08
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Two recent epidemiological investigations in children exposed to valproic acid (VPA) treatment in utero have reported a significant risk associated with neurodevelopmental disorders and autism spectrum disorder (ASD) in particular. Parallel to this work, there is a growing body of animal research literature using VPA as an animal model of ASD. In this focused review we first summarize the epidemiological evidence linking VPA to ASD and then comment on two important neurobiological findings linking VPA to ASD clinicopathology, namely, accelerated or early brain overgrowth and hyperexcitable networks. Improving our understanding of how the drug VPA can alter early development of neurological systems will ultimately improve our understanding of ASD.
Description
Keywords
Citation
Taylor Chomiak, Nathanael Turner, and Bin Hu, “What We Have Learned about Autism Spectrum Disorder from Valproic Acid,” Pathology Research International, vol. 2013, Article ID 712758, 8 pages, 2013. doi:10.1155/2013/712758